Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 8/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.58 |
| ▸ | PDE4A | P27815 | 3/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3423318 | 0.76 | ADORA2B (1.00) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL9574927 | 0.74 | ADORA2B (0.64) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL2837684 | 0.74 | ADORA2B (0.64) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL618977 | 0.74 | ADORA2B (0.64) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL9949244 | 0.74 | ADORA2B (0.64) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| 1-Methylxanthine SCHEMBL10996 | 0.74 | ADORA2B (1.00) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL28648091 | 0.74 | ADORA2B (0.64) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL447390 | 0.74 | ADORA2B (0.64) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL28516221 | 0.74 | ADORA2B (0.64) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL5510062 | 0.74 | ADORA2B (0.64) | ADORA2BADORA3ADORA2APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016159745-A1 | ETHYNYLXANTHINES, PREPARATION AND USE FOR CANCER TREATMENT | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016159745-A1 | ETHYNYLXANTHINES, PREPARATION AND USE FOR CANCER TREATMENT | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016159747-A1 | ETHYNYLXANTHINES, PREPARATION AND USE AS CALCIUM ION CHANNEL MODULATORS | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016159746-A1 | NOVEL ETHYNYLXANTHINES, THEIR PREPARATION AND USE AS INHIBITORS OF MATRIX METALLOPROTEINASES AND ANGIOGENESIS | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016159746-A1 | NOVEL ETHYNYLXANTHINES, THEIR PREPARATION AND USE AS INHIBITORS OF MATRIX METALLOPROTEINASES AND ANGIOGENESIS | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2016-10-06 | — | — | WO | disclosed |
| EP-2097415-B1 | 8-ETHINYLXANTHINE DERIVATIVES AS SELECTIVE A2A RECEPTOR ANTAGONISTS | UNIV BONN (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-8044061-B2 | Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. | UCB PHARMA GMBH (DE) | 2011-10-25 | — | — | US | disclosed |
| EP-2097415-A1 | 8-ETHINYLXANTHINE DERIVATIVES AS SELECTIVE A2A RECEPTOR ANTAGONISTS | Schwarz Pharma AG (DE) | 2009-09-09 | — | — | EP | disclosed |
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008077557-A1 | 8-ETHINYLXANTHINE DERIVATIVES AS SELECTIVE A2A RECEPTOR ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | SLC6A3, PARK7, SLC18A2 | ADORA2B 279/4885ADORA3 248/4885ADORA2A 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.